Prescription medicine
Dibasic and monobasic
Dibasic and monobasic is a prescription medicine. FDA's NDC Directory lists it from 4 generic labelers.
- Generic listed
Check it at the source: the dibasic and monobasic FDA label on DailyMed (effective February 28, 2025, Fresenius Kabi USA, LLC); every dibasic and monobasic label on DailyMed.
Highlights of the record
FDA label of February 28, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usagePotassium Phosphates Injection is indicated as a source of phosphorus:
in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated.
Forms and strengths
- 4.48 mg/ml / 4.72 mg/ml
- 11.2 mg/ml / 11.8 mg/ml
- 224 mg/ml / 236 mg/ml
Injection (solution) (concentrate); injection (solution); injection.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 6 of which 4 under generic applications, 2 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 867 through July 30, 2026
What is dibasic and monobasic used for?
From the label: indications and usagePotassium Phosphates Injection is indicated as a source of phosphorus:
in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated.
for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. Potassium Phosphates Injection is a phosphorus replacement product indicated as a source of phosphorus:
in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. […]
FDA pharmacologic class: Osmotic Laxative and Potassium Salt.
Source: FDA drug label (Potassium Phosphates), Fresenius Kabi USA, LLC, effective February 28, 2025 (SPL set 475f5cd7-45bd-412a-b419-9962585d6cda), via openFDA; the full label on DailyMed
Is there a generic for dibasic and monobasic?
No generic dibasic and monobasic is approved (Drugs@FDA, October 8, 2026).
FDA's NDC Directory lists dibasic and monobasic from 4 labelers under a generic (ANDA) application and from 2 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the dibasic and monobasic label say about other medicines?
The dibasic and monobasic label names 3 other medicines in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Cyclosporine | drug interactions | … diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions ( 5.3 )]. |
| Digoxin | drug interactions | Products that Increase Serum Potassium Administration of Potassium Phosphates Injection to patients treated concurrently or recently with products that increase serum potassium (e.g., potassium- sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and … |
| Tacrolimus | drug interactions | … sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, digoxin, or the immunosuppressants tacrolimus and cyclosporine) increases the risk of severe and potentially fatal hyperkalemia, in particular in the presence of other risk factors for hyperkalemia [see Warnings and Precautions ( 5.3 )]. |
Source: FDA drug label (Potassium Phosphates), Fresenius Kabi USA, LLC, effective February 28, 2025 (SPL set 475f5cd7-45bd-412a-b419-9962585d6cda), via openFDA; the full label on DailyMed
What do FAERS reports show for dibasic and monobasic?
The FDA Adverse Event Reporting System holds 867 reports that list dibasic and monobasic among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 170 are coded as a death and 511 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Other osmotic laxatives
- the pharmacologic class, with prices and generics
- Dibasic and monobasic side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other